Navigation Links
PDL BioPharma Announces Second Quarter 2009 Financial Results
Date:7/30/2009

INCLINE VILLAGE, Nev., July 30 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the second quarter ended June 30, 2009.

Total revenues from continuing operations for the second quarter of 2009 were $125.9 million, an 18 percent increase from $106.5 million for the same period in 2008. The increase was due primarily to royalty revenues driven by higher product sales of Avastin(R), and Lucentis(R), which are marketed by Genentech, Inc., a subsidiary of F. Hoffman-LaRoche Ltd., and sales of Tysabri(R), which is marketed by Elan Corporation Plc. and Biogen Idec Inc. Royalty revenues are based on first quarter 2009 product sales by PDL's licensees and include $18.9 million for Synagis(R), which is marketed by MedImmune, Inc. Also included in the second quarter revenue was the second and final installment of $12.5 million from Alexion Pharmaceuticals, Inc. based on the companies' December 2008 settlement and license agreement. When compared with 2008, royalty revenue for foreign sourced sales was negatively impacted by changes in foreign exchange rates; approximately 50 percent of underlying product sales is in currencies other than U.S. dollars.

"We have seen significant increases in sales of Tysabri and other products in our licensing portfolio, demonstrating that these products are fulfilling the promise of the underlying humanization technology," said John McLaughlin, president and chief executive officer of PDL BioPharma. "We paid our first post spin-off dividend to stockholders this quarter, and expect to pay the second dividend on October 1 as we continue to optimize our assets to benefit stockholders."

Total general and administrative expenses from continuing operations in the second quarter of 2009 were $5.6 million compared with $10.9 million in the second quarter of 2008. The decrease was primarily driven by the Company's reduced cost structure. Significant expense items for the second quarter of 2009 are legal fees of $2.7 million, professional fees and insurance of $1.0 million, compensation and benefits of $0.8 million, costs associated with monetization efforts of $0.3 million and non-cash stock compensation costs of $0.2 million. Net income for the second quarter of 2009 was $77.2 million, or $0.47 per diluted share, compared with a net income of $33.9 million in the same period of 2008, or a net income of $0.24 per diluted share.

Also in the second quarter, the Company made open market purchases totaling $55 million of its 2% convertible notes due in 2012 and its 2.75% convertible notes due in 2023.

Net cash provided by operating activities was $103.4 million for the first half of 2009 as compared with net cash provided by operating activities of $7.5 million for the first half of 2008. At June 30, 2009, PDL had cash, cash equivalents, short-term investments and restricted cash of $192.7 million, compared with $147.5 million at December 31, 2008.

2009 Dividends

PDL previously announced that it would pay two dividends to its stockholders in 2009 of $0.50 per share. The first dividend, totaling $59.7 million, was paid on April 1, 2009 to all stockholders who owned shares of PDL on March 16, 2009. The second dividend will be paid on October 1, 2009 to all stockholders who own shares of PDL on September 17, 2009.

2009 Financial Guidance

PDL reaffirms its previous revenue guidance and continues to anticipate strong revenue growth in 2009 increasing from 2008 to a range of $310 to $325 million excluding MedImmune royalties. Revenue growth expectations are primarily driven by increases in product sales of Avastin, Herceptin, Lucentis and Tysabri.

PDL expects its general and administrative expenses for 2009 to range from $20 to $22 million, of which approximately 50 percent is related to legal expense, patent defense and other professional fees. Net income after taxes for 2009 including MedImmune is projected in the range of $200 to $215 million and cash generated in 2009 is expected to be in the range of $285 to $300 million. PDL had previously guided that net income would be in the range of $185 to $200 million and cash generated in 2009 to be in the range of $260 to $280 million.

Conference Call Details

To access the live conference call via phone, please dial (866) 510-0707 from the United States and Canada or (617) 597-5376 internationally. The conference ID is 27369299. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through August 6, and may be accessed by dialing (888) 286-8010 from the United States and Canada or (617) 801-6888 internationally. The replay passcode is 58547023.

To access the live and subsequently archived webcast of the conference call, go to the company's Web site at http://www.pdl.com and click "Investors." Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma, Inc.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements

This press release contains forward-looking statements, including PDL's expectations with respect to its 2009 royalty revenues, expenses, net income and cash provided by operating activities.

Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

  • The expected rate of growth in royalty-bearing product sales by PDL's existing licensees;
  • The relative mix of royalty-bearing products manufactured and sold outside the U.S. versus manufactured or sold in the U.S.;
  • The ability of our licensees to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, will be commercially successful;
  • Changes in any of the other assumptions on which PDL's projected royalty revenues are based;
  • The outcome of pending litigation or disputes; and
  • The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.

Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL's filings with the SEC, including the "Risk Factors" sections of its annual and quarterly reports filed with the SEC. Copies of PDL's filings with the SEC may be obtained at the "Investors" section of PDL's website at www.pdl.com. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

                       -Financial statements below-

                             PDL BIOPHARMA, INC.
               CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                   (in thousands, except per share amounts)
                                 (unaudited)

                                        Three                Six
                                     Months Ended        Months Ended
                                       June 30,            June 30,
                                       --------            --------
                                      2009      2008      2009      2008
                                      ----      ----      ----      ----
    Revenues                      $125,864  $106,532  $188,486  $156,720
    General and administrative
     expenses                        5,590    10,925    10,283    23,634
                                     -----    ------    ------    ------
        Operating income           120,274    95,607   178,203   133,086
    Gain from repurchase of
     convertible notes               1,195         -     1,195         -
    Interest and other income,
     net                               310     4,467       646     9,331
    Interest expense                (3,357)   (3,555)   (6,931)   (7,110)
                                    ------    ------    ------    ------

        Income from continuing
         operations before income
         taxes                     118,422    96,519   173,113   135,307
    Income tax expense              41,185     1,673    58,419     2,707
                                    ------     -----    ------     -----
        Income from continuing
         operations                 77,237    94,846   114,694   132,600
    Loss from discontinued
     operations, net of income
     taxes (1)                           -   (60,914)        -  (160,543)

                                   -------   -------  --------  --------
        Net income (loss)          $77,237   $33,932  $114,694  $(27,943)
                                   =======   =======  ========  ========

    Income (loss) per basic share
        Continuing operations        $0.65     $0.80     $0.96     $1.12
        Discontinued operations          -     (0.51)        -     (1.36)
                                     -----     -----     -----     -----
          Net income (loss) per
           basic share               $0.65     $0.29     $0.96    $(0.24)
                                     =====     =====     =====    ======

    Income (loss) per diluted
     share
        Continuing operations        $0.47     $0.63     $0.69     $0.90
        Discontinued operations          -     (0.39)        -     (1.06)
                                     -----     -----     -----     -----
          Net income (loss) per
           diluted share             $0.47     $0.24     $0.69    $(0.16)
                                     =====     =====     =====    ======

    Cash dividends declared per
     common share                       $-        $-     $1.00        $-
                                       ===       ===     =====       ===

    Shares used to compute income
     (loss) per basic share        119,357   118,827   119,342   118,176
                                   =======   =======   =======   =======
    Shares used to compute income
     (loss) per diluted share      169,566   152,455   171,053   152,056
                                   =======   =======   =======   =======

    (1) The financial results associated with both PDL's former commercial
    operations which were sold in March 2008 and PDL's former biotechnology
    operations which were spun off in December 2008 have been presented as
    discontinued operations for the three and six months ended June 30, 2008.
    There were no discontinued operations for the three and six months ended
    June 30, 2009.



                              PDL BIOPHARMA, INC.
                   CONDENSED CONSOLIDATED BALANCE SHEET DATA
                                (in thousands)
                                  (unaudited)

                                                   June 30,     December 31,
                                                     2009          2008
                                                     ----          ----
    Cash, cash equivalents, short-term investments
     and restricted cash                            $192,702      $147,527
    Total assets                                    $217,895      $191,142
    Total stockholders' deficit                    $(306,982)    $(352,569)



           CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW DATA
                             (in thousands)
                               (unaudited)

                                                   Six  Months Ended
                                                       June 30,
                                                       --------
                                                      2009      2008
                                                      ----      ----
    Net income (loss)                             $114,694  $(27,943)
    Adjustments to reconcile net income (loss) to
     net cash provided by operating activities      (4,818)   42,683
    Changes in assets and liabilities               (6,503)   (7,226)
                                                    ------    ------
    Net cash provided by operating activities     $103,373    $7,514
                                                  ========    ======



                           PDL BIOPHARMA, INC.
         SUPPLEMENTAL INFORMATION ON DISCONTINUED OPERATIONS (1)
                              (in thousands)
                               (unaudited)


    Biotechnology Operations            Three Months     Six Months
                                       Ended June 30,  Ended June 30,
                                       --------------  --------------
                                       2009     2008  2009      2008
                                       ----     ----  ----      ----
    Net revenues                         $-   $5,361    $-   $12,502
    Total costs and expenses              -  (49,747)    -   (65,071)
    Income tax benefit                    -      309     -       339
                                        ---      ---   ---       ---
    Loss from discontinued operations    $- $(44,077)   $-  $(52,230)
                                        === ========   ===  ========




    Commercial Operations               Three Months     Six Months
                                       Ended June 30,  Ended June 30,
                                       --------------  --------------
                                       2009     2008  2009      2008
                                       ----     ----  ----      ----
    Net revenues                         $-     $375    $-   $39,734
    Total costs and expenses              -   (5,188)    -  (107,995)
    Income tax expense                    -  (12,024)    -   (40,052)
                                        ---  -------   ---   -------
    Loss from discontinued operations    $- $(16,837)   $- $(108,313)
                                        === ========   === =========

    (1) The financial results associated with both PDL's former commercial
    operations which were sold in March 2008 and PDL's former biotechnology
    operations which were spun off in December 2008 have been presented as
    discontinued operations for the three and six months ended June 30, 2008.
    There were no discontinued operations for the three and six months ended
    June 30, 2009.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PDL BioPharma to Announce Second Quarter 2009 Financial Results and Hold Conference Call July 30, 2009
2. DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller
3. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
4. Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF
5. Sinobiopharma Receives Trademark Approval and Authentication From Chinese Government For Its Tai Drug Series
6. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
7. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
8. PDL BioPharma Announces Record Date for October 1 Dividend Payment
9. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
10. SAFE-BioPharma Webinar Featuring ARX's Digital Signatures Combined with Microsoft SharePoint for Bio-Pharma industry
11. Prix Galien USA Now Accepting Nominations for Premiere Biopharmaceutical Industry Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology: